Carrick Therapeutics Limited   Report issue

For profit Phase 2
Founded: Dublin Ireland (2015)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2017
NCT03363893
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Carrick Therapeutics Limited

Active Ingredients

Drugs in Phase 2 Trials (2)

ct7001 (1 trial)

fulvestrant (faslodex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2